Mirna Therapeutics is a microRNA in therapeutics company founded in 2007 and is based out of Austin Texas. Mirnas current focus is on cancer research so it came as no surprise when they made the announcement that Clay Seigall would be joining the board of directors as an outside Director. Seigall has been the leading force behind ground breaking cancer treatments and he will be a welcome addition to the Mirna board to provide scientific knowledge as well as practical experience. Seigall received his PHD in genetics from George Washington University and then went on to found Seattle Genetics in 1998 of which he is now the Chief Executive Officer and a board member. Seigall has built Seattle Genetics into a state of the art research firm founded on the principals of integrity, scientific excellence, innovation, teamwork and most importantly helping patients.
With his scientific background, Seigall made the company’s focus about antibody-based therapies for the treatment of cancer. With this focus Seattle Genetics went on the develop the first of its kind antibody drug conjugates (ADCs) that was approved by the FDA in 2011. Seigall then lead the way to form multiple relationships with the larger drug companies to further the development of these treatments. In addition to the multiple collaborations, Seattle Genetics has additional treatments in the pipeline in various phases with the ultimate goal of FDA approval. Seigall is also credited with raising over $675 in both private and public funding to help advance the company’s research efforts.
With the success of Seattle Genetics it is no surprise the Mirna Board wanted Seagalls expertise. In addition to sitting on the board of Mirna, Seigall also joined the board of Ultragenyx in January of 2014. Ultragenyx is a biopharmaceutical company that focuses on research for rare and ultra-rare genetic diseases. Seigall is also a board member of Alder BioPharmaceuticals a therapeutic antibodies research firm dedicated to the treatment of chronic migraines, autoimmune diseases, and inflammatory diseases. It is clear that Seigall has dedicated his life to working with various organizations to help advance the treatment of people who are suffering from various diseases.
Keep up with Clay Siegall’s blog: